publication date: Mar. 6, 2020
NCI Trials for March 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10317
A Pilot Study of Nivolumab in Combination with Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center LAO
Mims, Alice Scott
Phase I – 10324
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum – Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Grisham, Rachel Nicole
Phase I – FOR0003
A Phase I Trial of D2C7-IT in Combination with Atezolizumab in Recurrent WHO Grade IV Malignant Glioma
Duke University Medical Center
Randazzo, Dina Marie
Phase II – ARST1921
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Children’s Oncology Group
Phase II – S1900B
A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Elamin, Yasir Y.
Phase III – NRG-GU008
Randomized Phase III Trial … Continue reading NCI Trials for March 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.